Ana Clara Ciglioni Salustiano^1,2, Gabriela Barbosa^1,3,4, Rodolfo Borges dos Reis^2,4, Amílcar Castro de Mattos^5,6, Athanase Billis⁶, Leonardo O. Reis^1,3,4,*

Oncology Research, Vol.33, No.11, pp. 3417-3428, 2025, DOI:10.32604/or.2025.068023 - 22 October 2025

Abstract Objective: The tumor microenvironment plays a pivotal role in prostate cancer progression and may differ across metastatic sites. This study aimed to evaluate and compare the primary and metastatic prostate adenocarcinoma tumor microenvironment. Methods: A total of 27 formalin-fixed paraffin-embedded tissue samples derived from 17 patients diagnosed with prostate adenocarcinoma, including the primary tumors, and the corresponding metastatic lymphatic and hematogenous lesions from various anatomical sites. Immunohistochemical labeling was performed using antibodies against Cluster of Differentiation 3 epsilon chain (CD3e), CD8 alpha chain (CD8a), Cluster of Differentiation 68 (CD68), Cluster of Differentiation 163 (CD163), Forkhead… More > Graphic Abstract

Filomena Emanuela Laddaga¹, Pamela Pinto², Bruna Daraia², Antonio D’amato^3,4, Stella D’oronzo^3,5, Stefano Martinotti^3,6,*, Francesco Gaudio^2,3,*

BIOCELL, Vol.49, No.7, pp. 1185-1206, 2025, DOI:10.32604/biocell.2025.063572 - 25 July 2025

Abstract Checkpoint inhibitors, particularly programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, have significantly advanced the treatment of Hodgkin lymphoma (HL), especially in relapsed or refractory cases. However, challenges such as resistance, immune-related adverse events (irAEs), and the need for effective patient selection remain. This review aims to explore the mechanisms of resistance to checkpoint inhibitors, including alterations in the tumor microenvironment, loss of antigen presentation, and T-cell exhaustion. Overcoming resistance may involve combination therapies, such as pairing PD-1 inhibitors with other immune checkpoint inhibitors or targeted therapies like Brentuximab vedotin. Additionally, next-generation inhibitors targeting molecules like More >

CHENXIAO QIAO¹, YIPENG XU², YEDIE HE², ZHIJIAN CAI^1,*, HUA WANG^2,*

Oncology Research, Vol.33, No.5, pp. 1161-1172, 2025, DOI:10.32604/or.2024.055746 - 18 April 2025

Abstract Objective: To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab. Methods: Anti-tumor efficacy of intratumoral injection of H101 or/and intraperitoneal injection of Camrelizumab were evaluated in an immune system humanized NOD Prkdc^scid Il2rg^-/- mice subcutaneous (S.C.) tumor model, established with human glioblastoma of unknown origin cell line U87-MG, and human bladder cancer cell line T24 and YTS-1. The mechanism by which H101 induced anti-tumor immunity were also investigated. Results: Combining H101 with Camrelizumab demonstrated more potent anti-tumor effects than monotherapy in… More >

SHUANG CHEN^1,2,#, XUEMEI DENG^2,#, XINGTING HE², KEWEI XIANG², GUIHONG CHEN², HONGRU YANG^2,*

Oncology Research, Vol.33, No.3, pp. 687-694, 2025, DOI:10.32604/or.2024.052133 - 28 February 2025

Abstract Background: Previous experiments have demonstrated that hypofractionated radiation therapy (HFRT), low-dose radiation therapy (LDRT), and combined anti-programmed cell death protein 1 (αPD-1) can enhance the abscopal effect. Combined with the phenomenon of low prognosis in patients with breast cancer lung metastasis, our study establishes a mouse model and changes the irradiation regimen of LDRT to explore its preventive effect on breast cancer lung metastasis. Methods: The breast cancer subcutaneous graft tumor model was developed. Two-lung prophylactic LDRT was performed prior to the onset of lung metastases, in combination with HFRT (8 Gy, 3f), and αPD-1… More >

EGOR V. BATOROV^1,2,*, ALISA D. INESHINA², TATIANA A. ARISTOVA³, VERA V. DENISOVA³, SVETLANA A. SIZIKOVA³, DARIA S. BATOROVA³, GALINA Y. USHAKOVA³, EKATERINA Y. SHEVELA¹, ELENA R. CHERNYKH¹

Oncology Research, Vol.32, No.10, pp. 1575-1587, 2024, DOI:10.32604/or.2024.047893 - 18 September 2024

Abstract Background: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules. Methods: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow… More >

SHUANGSHUANG ZENG^1,2, XI CHEN^1,2, QIAOLI YI^1,2, ABHIMANYU THAKUR³, HUI YANG^4,*, YUANLIANG YAN^1,2, SHAO LIU^1,2,*

Oncology Research, Vol.32, No.2, pp. 261-272, 2024, DOI:10.32604/or.2023.042345 - 28 December 2023

Abstract Finding biomarkers for immunotherapy is an urgent issue in cancer treatment. Cellular retinoic acid-binding protein 2 (CRABP2) is a controversial factor in the occurrence and development of human tumors. However, there is limited research on the relationship between CRABP2 and immunotherapy response. This study found that negative correlations of CRABP2 and immune checkpoint markers (PD-1, PD-L1, and CTLA-4) were observed in breast invasive carcinoma (BRCA), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD) and testicular germ cell tumors (TGCT). In particular, in SKCM patients who were treated with PD-1 inhibitors, high levels of CRABP2 predicted poor… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942 - 22 May 2023

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

PARISA SHIRI AGHBASH^1,2,4, NIMA HEMMAT¹, BEHZAD BARADARAN^1,3, AHAD MOKHTARZADEH¹, VAHDAT POORTAHMASEBI^2,4, MAHIN AHANGAR OSKUEE^2,4, HOSSEIN BANNAZADEH BAGHI^1,2,4,*

Oncology Research, Vol.30, No.3, pp. 99-116, 2022, DOI:10.32604/or.2022.026776 - 12 January 2023

Abstract Infection with high-risk human papillomavirus (HPV), including HPV-16 and HPV-18, is the main cause of malignancies, such as cervical cancer. Viral oncoproteins encoded by HPV are expressed in HPV-positive cancers and associated with the early cancer stages and the transformation of normal cells. The signaling pathways involved in the transformation of normal cells to cancerous form and the subsequently expressed programmed cell death-ligand 1 (PD-L1) on the surface of the transformed cells lead to a disruption in recognition of tumor cells by the immune cell system, including T lymphocytes and dendritic cells which lead to… More > Graphic Abstract

Yu Xiao^1,2,#, Jianping Jiang^3,#, Yan Chen^1,4, Yi Huang¹, Changyuan Wei^1,*

Oncologie, Vol.24, No.4, pp. 729-742, 2022, DOI:10.32604/oncologie.2022.026118 - 31 December 2022

Abstract Background: Immunotherapy is becoming a powerful approach in the treatment of breast cancer. However, high response rates in the majority of breast cancer patients have yet to be achieved. Materials and Methods: Based on public data sources, we identified 22 genes that are correlated with PD-1 expression as well as differentially expressed between tumor tissues and normal tissues, and high expression of all the key genes was correlated with a superior survival outcome. Using the least absolute shrinkage and selection operator Cox regression model, a risk score was constructed. Results: A multivariate Cox analysis showed that the… More >

Luca Campedel^1,†, Thomas Seisen^1,†, Justine Varinot², Géraldine Cancel-Tassin^2,3,#, Alain Ruffion⁴, Emilien Seizilles De Mazancourt⁴, Myriam Decaussin-Petrucci⁵, Grégoire Robert⁶, Nam-Son Vuong⁶, Magali Philipp⁷, Eva Compérat^2,3,#, Morgan Rouprêt^1,3,#, Olivier Cussenot^2,3,#

Canadian Journal of Urology, Vol.28, No.3, pp. 10719-10724, 2021

Abstract Introduction: Controversy regarding the prognostic and/or predictive role of PD-1 and PD-L1 expression for upper tract urothelial carcinoma (UTUC) could partly be explained by inconsistencies in the immunohistochemistry (IHC) methodology. The objective is to standardize the methodology for routine evaluation of PD-1 and PD-L1 expression in UTUC patients.
Materials and methods: Twenty-two cases treated with radical nephroureterectomy between 1996 and 2015 at 11 French hospitals were randomly selected to compare different methodologies for evaluation of PD-1 and PD-L1 expression. IHC was carried out on whole tissue sections and 0.6 mm- or 2 mm-core tissue micro-arrays (TMAs) using… More >